LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2

International Immunopharmacology

Volumn 13, Issue 3, 2012, Pages 225-231

  Aul, Raminder ^a   Patel, Sheena ^b   Summerhill, Susan ^b   Kilty, Iain ^b   Plumb, Jonathan ^a   Singh, Dave ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Chemotaxis; COPD; CXCR1; CXCR2; Lipopolysaccharide; Neutrophils

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CXCL1 CHEMOKINE; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NAVARIXIN; SB 656933; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MALE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPUTUM EXAMINATION;

ADMINISTRATION, INHALATION; ADULT; BENZAMIDES; CHEMOKINE CCL2; CHEMOTAXIS, LEUKOCYTE; CYCLOBUTANES; FEMALE; HUMANS; INTERLEUKIN-6; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; MODELS, IMMUNOLOGICAL; NEUTROPHILS; PHENYLUREA COMPOUNDS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SPUTUM; SULFONAMIDES;

EID: 84861418098     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2012.04.008     Document Type: Article

References (33)

1. Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996;51:267-71. (Pubitemid 26086470)
2. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999;160:1532-9.
3. Macedo P, Hew M, Torrego A, Jouneau S, Oates T, Durham A, et al. Inflammatory biomarkers in airways of patients with severe asthma compared with nonsevere asthma. Clin Exp Allergy 2009;39:1668-76.
4. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines -CXC and CC chemokines. Adv Immunol 1994;55:97-179.
5. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
6. Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokuyama T, Tsukaguchi K, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112:505-10. (Pubitemid 27349446)
7. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002;57:590-5. (Pubitemid 34761760)
8. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulut AB, Temel I. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006;100:846-54.
9. Qiu Y, Zhu J, Bandi V, Guntupalli KK, Jeffery PK. Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 2007;62:475-82. (Pubitemid 46910124)
10. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705. (Pubitemid 27169296)
11. Owen C. Chemokine receptors in airway disease: which receptors to target? Pulm Pharmacol Ther 2001;14:193-202. (Pubitemid 32619924)
12. Jones SA, Wolf M, Qin S, Mackay CR, Baggiolini M. Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2. Proc Natl Acad Sci U S A 1996;93:6682-6. (Pubitemid 26230369)
13. Lazaar AL, Sweeney LE, Macdonald AJ, Alexis NE, Chen C, Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex-vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011;72(2):282-93.
14. Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35(3):564-70.
15. Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7. (Pubitemid 27334820)
16. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801. (Pubitemid 43261452)
17. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005;17:1-14.
18. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-65.
19. Sandstrom T, Bjermer L, Rylander R. Lipopolysaccharide (LPS) inhalation in healthy subjects increases neutrophils, lymphocytes and fibronectin levels in bronchoalveolar lavage fluid. Eur Respir J 1992;5:992-6.
20. Michel O, Nagy AM, Schroeven M, Duchateau J, Neve J, Fondu P, et al. Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med 1997;156:1157-64.
21. Nightingale JA, Rogers DF, Hart LA, Kharitonov SA, Chung KF, Barnes PJ. Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax 1998;53:563-71. (Pubitemid 28335516)
22. Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, et al. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005;172:878-84. (Pubitemid 41369072)
23. Michel O, Dentener M, Cataldo D, Cantinieaux B, Vertongen F, Delvaux C, et al. Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human. Pulm Pharmacol Ther 2007;20:676-83. (Pubitemid 47446344)
24. Yoshikawa T, Dent G, Ward J, Angco G, Nong G, Nomura N, et al. Impaired neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med Mar. 1 2007;175(5):473-9. (Pubitemid 46354251)
25. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308-17. (Pubitemid 26269096)
26. Boyden S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 1962;115:453-66.
27. Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J Pharmacol Exp Ther 2007;322:477-85. (Pubitemid 47105793)
28. Chapman RW, Philips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121:55-68.
29. Arndt PG, Strahan B, Wang Y, Long C, Horiuchi K, Walcheck B. Leukocyte ADAM17 regulates acute pulmonary inflammation. PLoS One 2011;6(5):e19938.
30. Reutershan J, Harry B, Chang D, Bagby GJ, Ley K. DARC on RBC limits lung injury by balancing compartmental distribution of CXC chemokines. Eur J Immunol Jun. 2009;39(6):1597-607.
31. O'Grady NP, Preas HL, Pugin J, Fiuza C, Tropea M, Reda D, et al. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med 2001;163:1591-8. (Pubitemid 32578761)
32. Capelli A, Di Stefano A, Gnemmi I, Balbo P, Cerutti CG, Balbi B, et al. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999;14:160-5. (Pubitemid 29411251)
33. Barczyk A, Pierzchala W, Sozanska E. Levels of CC-chemokine (MCP-1 alpha, MIP-1 beta) in induced sputum of patients with chronic obstructive pulmonary disease and patients with chronic bronchitis. Pneumonol Alergol Pol 2001;69:40-9.